XML 15 R56.htm IDEA: XBRL DOCUMENT v3.20.1
Fair Value Considerations (Details 2) - USD ($)
Mar. 31, 2020
Jun. 30, 2019
Right-to-use asset $ 675,980 $ 0
Fair Value, Measurements, Nonrecurring    
Total 88,694,836  
Level 1 | Fair Value, Measurements, Nonrecurring    
Total 0  
Level 2 | Fair Value, Measurements, Nonrecurring    
Total 0  
Level 3 | Fair Value, Measurements, Nonrecurring    
Total 88,694,836  
Cerecor, Inc. | Fair Value, Measurements, Nonrecurring    
Product technology rights 22,700,000  
Goodwill 15,687,064  
Fixed payment arrangements 26,457,162  
Cerecor, Inc. | Level 1 | Fair Value, Measurements, Nonrecurring    
Product technology rights 0  
Goodwill 0  
Fixed payment arrangements 0  
Cerecor, Inc. | Level 2 | Fair Value, Measurements, Nonrecurring    
Product technology rights 0  
Goodwill 0  
Fixed payment arrangements 0  
Cerecor, Inc. | Level 3 | Fair Value, Measurements, Nonrecurring    
Product technology rights 22,700,000  
Goodwill 15,687,064  
Fixed payment arrangements 26,457,162  
Innovus Pharmaceuticals | Fair Value, Measurements, Nonrecurring    
Customer lists 390,000  
Product distribution rights (trademarks and patents) 11,354,000  
Right-to-use asset 675,980  
Goodwill 8,374,269  
Notes payable 3,056,361  
Innovus Pharmaceuticals | Level 1 | Fair Value, Measurements, Nonrecurring    
Customer lists 0  
Product distribution rights (trademarks and patents) 0  
Right-to-use asset 0  
Goodwill 0  
Notes payable 0  
Innovus Pharmaceuticals | Level 2 | Fair Value, Measurements, Nonrecurring    
Customer lists 0  
Product distribution rights (trademarks and patents) 0  
Right-to-use asset 0  
Goodwill 0  
Notes payable 0  
Innovus Pharmaceuticals | Level 3 | Fair Value, Measurements, Nonrecurring    
Customer lists 390,000  
Product distribution rights (trademarks and patents) 11,354,000  
Right-to-use asset 675,980  
Goodwill 8,374,269  
Notes payable $ 3,056,361